Cargando…

Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs

BACKGROUND: Administrative healthcare claims data provide a mechanism for assessing and monitoring multiple sclerosis (MS) disease status across large, clinically representative “real-world” populations. The estimation of MS disease status using administrative claims can be a challenge, however, due...

Descripción completa

Detalles Bibliográficos
Autores principales:	Munsell, Michael, Frean, Molly, Menzin, Joseph, Phillips, Amy L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460356/ https://www.ncbi.nlm.nih.gov/pubmed/28583104 http://dx.doi.org/10.1186/s12883-017-0887-1

Ejemplares similares

An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug
por: Munsell, Michael, et al.
Publicado: (2016)

Comorbidity in US patients with multiple sclerosis
por: Edwards, Natalie C, et al.
Publicado: (2018)

Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis
por: Menzin, Joseph, et al.
Publicado: (2013)

Economic impact of infections among patients with primary immunodeficiency disease receiving IVIG therapy
por: Menzin, Joseph, et al.
Publicado: (2014)

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
por: Halpern, Rachel, et al.
Publicado: (2011)

A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies
por: Duquette, Pierre, et al.
Publicado: (2019)

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis
por: Fox, Robert J., et al.
Publicado: (2022)

Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies
por: Porwal, Mokshal H., et al.
Publicado: (2022)

MSR37 Identifying Clinical Subtypes of Long COVID: An Unsupervised Machine Learning Approach
por: Munsell, M., et al.
Publicado: (2023)

P9 Characteristics of Patients Diagnosed with Long COVID: Early Findings from Real-World Data
por: Munsell, M., et al.
Publicado: (2023)

Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data
por: Engmann, Natalie J, et al.
Publicado: (2021)

ML4 Application of Machine Learning Models to Evaluate COVID-19 Related ICU Utilization in a US Population
por: Icten, Z., et al.
Publicado: (2020)

Disease Modifying Agents for Multiple Sclerosis
por: Hilas, Olga, et al.
Publicado: (2010)

Disease-modifying agents in multiple sclerosis
por: Coyle, P. K.
Publicado: (2009)

Disease Modifying Therapy in Multiple Sclerosis
por: Williams, U. E., et al.
Publicado: (2014)

Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database
por: Boster, Aaron, et al.
Publicado: (2017)

Use of an Early Disease-Modifying Drug Adherence Measure to Predict Future Adherence in Patients with Multiple Sclerosis
por: Kozma, Chris M., et al.
Publicado: (2014)

Validation of claims-based indicators used to identify flare-ups in inflammatory bowel disease
por: Burisch, Johan, et al.
Publicado: (2021)

Multiple Sclerosis: Overview of Disease-Modifying Agents
por: Finkelsztejn, Alessandro
Publicado: (2014)

Oral Disease-Modifying Therapies for Multiple Sclerosis
por: Kim, Woojun, et al.
Publicado: (2015)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Multiple Sclerosis, Disease-Modifying Therapies, and Infections
por: Langer-Gould, Annette M., et al.
Publicado: (2023)

Adherence to Disease-Modifying Therapies for Multiple Sclerosis
por: Higuera, Lucas, et al.
Publicado: (2016)

Author response to comment on: Alopecia in multiple sclerosis patients treated with disease modifying therapies
por: Porwal, Mokshal H., et al.
Publicado: (2022)

Ischemia modified albumin is an indicator of oxidative stress in multiple sclerosis
por: Aydin, Ozgur, et al.
Publicado: (2014)

Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data
por: Nicholas, Jacqueline, et al.
Publicado: (2017)

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
por: Freeman, Leorah, et al.
Publicado: (2021)

Current treatment status and medical cost for multiple sclerosis based on analysis of a Japanese claims database
por: Ogino, Mieko, et al.
Publicado: (2016)

Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis
por: Kawachi, Izumi, et al.
Publicado: (2022)

Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies
por: Baba, Cavid, et al.
Publicado: (2022)

Use of a medication-based algorithm to identify advanced Parkinson's disease in administrative claims data: Associations with claims-based indicators of disease severity
por: Dahodwala, Nabila, et al.
Publicado: (2020)

New oral disease-modifying therapies for multiple sclerosis
por: Bagert, Bridget A, et al.
Publicado: (2009)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Adherence to disease-modifying therapies in patients with multiple sclerosis
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2018)

Disease-modifying therapies in multiple sclerosis in Latin America
por: Skromne-Eisenberg, Eli, et al.
Publicado: (2017)

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
por: Jalkh, Georges, et al.
Publicado: (2020)

Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
por: Ng, Huah Shin, et al.
Publicado: (2022)

Drug-use patterns and severe adverse events with disease-modifying drugs in patients with multiple sclerosis: a cohort study based on German claims data
por: Simbrich, Alexandra, et al.
Publicado: (2019)

Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population
por: Molazadeh, Negar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7tsq6fl87e1oe8q80l34682g23